Full text
Earnings transcript
Read the complete earnings call transcript.
MDT
Medtronic plc
$81.98
1.29
(1.6%)
| Exchange: | NYSE |
| Market Cap: | 105.253B |
| Shares Outstanding: | 890M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Geoffrey Straub Martha | |||||
| Full Time Employees: | 95000 | |||||
| Address: |
| |||||
| Website: | https://www.medtronic.com |
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company’s operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain’s vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 32,364,000 | 33,537,000 | 36,364,000 |
| Gross Profit | 21,148,000 | 21,905,000 | 23,643,000 |
| EBITDA | 8,203,000 | 9,218,000 | 6,851,000 |
| Operating Income | 5,144,000 | 5,955,000 | 6,467,000 |
| Net Income | 3,676,000 | 4,662,000 | 4,800,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 90,948,000 | 89,981,000 | 91,680,000 |
| Total Liabilities | 39,283,000 | 39,561,000 | 43,424,000 |
| Total Stockholders Equity | 51,483,000 | 50,214,000 | 48,024,000 |
| Total Debt | 24,364,000 | 25,024,000 | 28,516,000 |
| Cash and Cash Equivalents | 1,543,000 | 1,284,000 | 2,218,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | 6,787,000 | 7,044,000 | 7,330,000 |
| Capital Expenditure | -1,587,000 | -1,859,000 | -1,904,000 |
| Free Cash Flow | 5,200,000 | 5,185,000 | 5,426,000 |
| Net Income | 3,676,000 | 4,691,000 | 0 |
| Net Change in Cash | -259,000 | 934,000 | 0 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 44,192,706.516 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 47,546,892.008 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 46,572,900 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 12,718,849.585 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 13,684,198.488 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 13,403,879.430 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 9,890,727.381 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 10,882,667.430 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 10,594,622.508 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 14,588,103.556 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 15,695,327.104 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 15,373,810.334 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 8.230 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 8.450 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 7.680 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 5 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Delivered 4.1% organic revenue growth in fiscal Q3 2025, exceeding analyst expectations through operational execution.
- Positioned for sustained performance via targeted strategic investments and product innovation in core medical technology segments.
- Maintains a diversified revenue base across product categories and geographic regions, supporting resilience in the healthcare sector.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates MDT intrinsic value between $57.52 – $89.80 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about MDT valuation
Is Medtronic plc (MDT) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Medtronic plc (MDT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is MDT a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MDT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is MDT’s P/E ratio?
You can see MDT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for MDT?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is MDT a good long-term investment?
Whether MDT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
MDT
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.6
Trading Metrics:
| Open: | 80.76 | Previous Close: | 80.69 | |
| Day Low: | 80.6 | Day High: | 82.34 | |
| Year Low: | 73.31 | Year High: | 106.33 | |
| Price Avg 50: | 81.17 | Price Avg 200: | 92.4 | |
| Volume: | 9.443M | Average Volume: | 9.607M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeMDT full analysis
Hey everyone, welcome back to the channel. Today we're diving deep into Medtronic, ticker MDT, one of the biggest names in medical devices, and breaking down whether this stock deserves a spot in your portfolio right now. Medtronic just wrapped up what management is calling its best year in a decade, and the stock has been reacting to that momentum mixed with some sector headwinds. We're going to look at the numbers, the growth drivers, valuation, and what the setup…
